Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.07 USD 0.00(0%)
Last update at 2026-11-13T14:30:00Z
Market Cap
168.61M

Momentum Score

…

IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services. In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis. Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating disorders, and other Parkinsonian disorders. It has collaboration with Medidata to create neuroimaging clinical trials platform. The company is based in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.07
Low
0.07
High
52 Week Price Range
0.07
Low
0.07
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

IXICO plc provides digital analytics and imaging services for neuroscience clinical trials, focusing on neurodegenerative diseases. Growth may be driven by rising demand for validated imaging and digital biomarkers, increasing neurology R&D, and adoption of data-driven endpoints. Investors may find appeal in its niche expertise, technology platform and recurring trial service exposure.

Material risks include cyclical biopharma R&D and client concentration, competition from larger CROs and analytics firms, biomarker validation and regulatory uncertainty, and limited liquidity as a smaller public company.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.07
Dividend Yield
-
Revenue TTM
7.28M
Revenue Per Share
0.08
Gross Profit TTM
3.69M
Debt / Equity
0.02
ROE
-15.80%
Net Debt
-3.36M
ROCE
-20.65%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -2.45M -1.91M -1.36M 0.89M 1.16M
Net income -1.65M -2.00M -1.18M 1.03M 1.57M
Selling general administrative 2.49M 2.91M 4.17M 3.48M 3.58M
Selling and marketing expenses 1.67M 1.40M - - -
Gross profit 3.18M 2.71M 3.27M 5.24M 6.02M
Reconciled depreciation 0.41M 0.47M 0.62M 0.64M 0.61M
Ebit -2.43M -2.15M - 0.91M 1.12M
Ebitda -2.02M -1.95M - 1.56M 1.79M
Depreciation and amortization 0.41M 0.21M - - -
Operating income -2.55M -2.15M -1.44M 0.76M 1.16M
Other operating expenses 9.09M 7.92M - 0.69M 0.45M
Interest expense 0.02M 0.03M 0.03M 0.03M 0.02M
Tax provision -0.80M -0.09M -0.18M -0.15M -0.41M
Interest income 0.12M 0.09M 0.10M 0.01M 0.00M
Net interest income 0.10M 0.06M 0.08M -0.02M -0.02M
Income tax expense -0.80M 0.09M - -0.15M -0.41M
Total revenue 6.53M 5.77M 6.67M 8.64M 9.19M
Total operating expenses 5.74M 4.87M 8.10M 7.88M 8.03M
Cost of revenue 3.35M 3.06M 3.40M 3.40M 3.17M
Total other income expense net 0.10M 0.25M - - -
Net income from continuing ops -1.65M -2.00M -1.18M 1.03M 1.57M
Net income applicable to common shares - - - 1.03M 1.51M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 13.84M 11.19M 12.99M 14.65M 14.15M
Intangible assets 7.18M 6.37M 6.15M 4.59M 2.71M
Other current assets 0.80M 0.49M - 0.10M 0.11M
Total liab 2.10M 1.72M 1.56M 2.16M 2.93M
Total stockholder equity 11.74M 9.46M 11.43M 12.49M 11.22M
Other current liab 1.74M 1.15M - 0.85M 0.53M
Common stock 0.93M 0.48M - 0.48M 0.48M
Capital stock 0.93M 0.48M 0.48M 0.48M 0.48M
Retained earnings -10.78M 7.46M -7.36M -6.23M -7.34M
Other liab - - - 0.03M 0.11M
Cash 3.54M 1.79M 4.03M 5.77M 6.68M
Total current liabilities 2.06M 1.57M 1.28M 1.74M 2.15M
Net debt -3.36M -1.47M - - -
Short term debt 0.15M 0.16M - - -
Short long term debt total 0.18M 0.31M - - -
Other stockholder equity 21.59M 1.52M - -66.56M -66.46M
Property plant equipment - - - 0.82M 1.08M
Total current assets 6.23M 4.49M 6.29M 9.25M 10.47M
Net tangible assets - - - 7.91M 8.77M
Net receivables 1.90M 2.21M 0.94M 2.73M 3.12M
Accounts payable 0.07M 0.08M 0.09M 0.25M 0.73M
Accumulated other comprehensive income 9.89M 9.84M - - -
Non currrent assets other 0.26M 0.01M - - -
Non current assets total 7.61M 6.70M 6.70M 5.40M 3.79M
Capital lease obligations 0.18M 0.31M 0.39M 0.52M 0.60M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - -0.38M -1.86M -2.24M -2.15M
Change to liabilities - - - -0.70M -0.37M
Total cashflows from investing activities -0.75M -0.38M - -2.24M -2.15M
Net borrowings - - - -0.11M -0.04M
Total cash from financing activities 3.50M -0.13M - -0.11M 0.27M
Net income -1.65M -2.00M -1.18M 1.03M 1.51M
Change in cash 1.75M -2.24M -1.72M -0.92M -1.26M
Begin period cash flow 1.79M 4.03M 5.77M 6.68M 7.95M
End period cash flow 3.54M 1.79M 4.03M 5.77M 6.68M
Total cash from operating activities -1.01M -1.73M 0.30M 1.42M 0.61M
Issuance of capital stock 3.70M 0.00M 0.00M 0.00M 0.31M
Depreciation 0.41M 0.47M 0.62M 0.49M 0.50M
Other cashflows from investing activities -0.69M -0.34M - 0.01M 0.00M
Change to account receivables 0.26M -0.56M - 0.28M -1.09M
Other cashflows from financing activities -0.19M -0.13M - - -
Change to netincome - - - 0.17M -0.05M
Capital expenditures 0.87M 0.47M 1.96M 0.19M 0.17M
Change in working capital 0.42M -0.21M 0.96M -0.42M -1.52M
Stock based compensation 0.23M 0.01M 0.05M 0.08M 0.20M
Other non cash items -0.41M -0.01M -0.43M -0.29M -0.19M
Free cash flow -1.88M -2.20M -1.66M -0.82M -1.54M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PHYOF
IXICO plc
-
-%
0.07 - 41.49 23.18 0.26 0.40 4.14
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

IXICO plc

IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services. In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis. Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating disorders, and other Parkinsonian disorders. It has collaboration with Medidata to create neuroimaging clinical trials platform. The company is based in London, the United Kingdom.

Griffin Court, London, United Kingdom, EC1A 9PN

44 20 3763 7499

79

Name Title Year Born
Mr. Giulio Cerroni CEO & Director 1962
Mr. Grant Nash CFO, Company Sec. & Exec. Director NA
Prof. Daniel Rueckert Co-Founder & Member of Scientific Advisory Board NA
Prof. Derek Lionel Glendon Hill Co-Founder and Pres of Regulatory Science & External Relations 1966
Prof. David Hawkes Co-Founder & Member of Scientific Advisory Board NA
Prof. Joseph Hajnal Co-Founder & Member of Scientific Advisory Board NA
Mr. Marcus Thornton Chief Operating Officer NA
Mr. Mark Austin Director of Technology NA
Dr. Robin Wolz Chief Scientific Officer NA
Ms. Hannah Esfahanian HR Mang. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…